Tamieka Alston-Gibson
Primary Care · Spartanburg, SCNPI 1902273808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $235, 2.2 times the $109 reported in 2022. That places this record below the midpoint for primary care clinicians in SC, where the typical reported total is $632.
Across 34 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$92
- Neurocrine Biosciences, Inc.$89
- Astellas Pharma US Inc$78
- AbbVie$74
- Novo Nordisk$59
- Teva Pharmaceuticals USA, Inc.$46
- plus $215 from 10 others
What the payments were for
- Food & beverage$653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 6 | $92 |
| Neurocrine Biosciences, Inc. | 4 | $89 |
| Astellas Pharma US Inc | 3 | $78 |
| AbbVie | 4 | $74 |
| Novo Nordisk | 4 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Inari Medical, Inc. | 1 | $36 |
| Abbott | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$653 in reported general payments places this provider in the 50th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $97,511 |
| OzempicSemaglutide | 43 | $43,545 |
| FarxigaDapagliflozin Propanediol | 51 | $30,577 |
| EliquisApixaban | 42 | $27,439 |
| RybelsusSemaglutide | 14 | $18,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,127 |
| XareltoRivaroxaban | 15 | $13,638 |
| JardianceEmpagliflozin | 20 | $13,141 |
| LinzessLinaclotide | 13 | $8,971 |
| JanuviaSitagliptin Phosphate | 11 | $6,780 |
| Fluphenazine Hcl | 18 | $5,378 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,280 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,750 |
| MyrbetriqMirabegron | 12 | $3,660 |
| Atorvastatin Calcium | 245 | $3,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $46 | $98,59825 claims |
| Novo NordiskOzempic, Rybelsus | $59 | $62,28157 claims |
| AbbVieLinzess | $74 | $8,97113 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $3,66012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 115 primary care providers in South Carolina.
Other primary care in Spartanburg
- Elizabeth CalicuttSpartanburg$4K
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.